Debiopharm, Quartz Bio Collaborate on NGS, Biomarker Data Analyses | GenomeWeb

NEW YORK (GenomeWeb News) – The Debiopharm Group said on Thursday it has inked a one-year collaboration deal with Quartz Bio for support of the biopharmaceutical group’s translational projects.

Quartz Bio, a clinical bioinformatics firm spun out by Merck Serono last September, will provide its expertise in computational analyses and biomarker discovery to Debiopharm’s projects, which are anticipated to range from next-generation sequencing and clinical biomarker data analyses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.